Klinikum Dortmund gGmbH
- Address
- lock Available on a paid plan
Oncology – Neoplasms
Clinical research at Klinikum Dortmund gGmbH focuses on solid tumors and hematologic malignancies, testing new therapies to improve survival and disease control.
- Cutaneous melanoma
- Hepatocellular carcinoma
- High‑risk medulloblastoma
- Advanced ovarian cancer
- Biliary tract cancer
- Hodgkin lymphoma
- Rhabdomyosarcoma
Emphasis is placed on immunotherapy, targeted agents, and combination regimens to enhance disease‑free survival.
Cardiovascular & Thrombotic Disorders
Trials aim to reduce recurrent events in patients with stroke, high‑risk transient ischemic attack, and anticoagulation‑related bleeding, evaluating novel antithrombotic strategies.
- Acute ischemic stroke
- High‑risk transient ischemic attack
- Factor Xa inhibitor reversal
- Milvexian for stroke prevention
- Tenecteplase adjunct therapy
- Sodium bicarbonate in metabolic acidosis
- Heart failure in kidney disease
Studies explore oral anticoagulant management and new agents to lower ischemic risk while ensuring safety.
Neurology – Brain Disorders
Research targets severe seizure conditions, multiple sclerosis, and pediatric brain tumors, seeking to improve neurological outcomes and quality of life.
- Benzodiazepine‑resistant status epilepticus in elderly
- Relapsing multiple sclerosis
- High‑risk medulloblastoma
- Ependymoma
- Neuroblastoma with CNS involvement
- Pediatric brain tumors
- Cognitive outcomes after medulloblastoma therapy
Trials incorporate novel anticonvulsants, immunotherapies, and precision radiotherapy to enhance disease control.
Renal and Metabolic Disorders
Studies address acute and chronic kidney injury, polycystic kidney disease, and metabolic acidosis, aiming to preserve renal function and reduce complications.
- Acute kidney injury
- Chronic kidney disease
- Autosomal dominant polycystic kidney disease
- Metabolic acidosis in critical illness
- Sodium bicarbonate therapy
- SGLT2 inhibition in ADPKD
- Dapagliflozin for kidney protection
Emphasis is on early intervention and combined heart‑kidney management strategies.
Immune‑Mediated and Skin Conditions
Clinical trials evaluate biologic and topical treatments for inflammatory skin diseases, focusing on symptom relief and long‑term disease control.
- Hidradenitis suppurativa
- Prurigo nodularis
- Vitiligo
- Scabies
- Moderate‑to‑severe psoriasis
- Atopic dermatitis
Targeted biologics and optimized topical regimens are being tested to improve patient quality of life.
Pediatric Oncology & Hematology
Dedicated programs for childhood cancers use genetic risk stratification and immunotherapy to boost event‑free survival while minimizing toxicity.
- Infant acute lymphoblastic leukemia
- Ph+ acute lymphoblastic leukemia
- High‑risk neuroblastoma
- Low‑risk neuroblastoma
- Medulloblastoma
- Ependymoma
- Childhood renal tumors
Trials incorporate novel chemo‑immunotherapy combos and reduced‑intensity chemotherapy schedules.
Respiratory and Infectious Diseases
Research includes chronic lung conditions and parasitic infections, aiming to improve pulmonary function and eradicate disease.
- Bronchiectasis
- Chronic back pain (as related to respiratory mechanics)
- Scabies
- Critical illness with respiratory failure
- Metabolic acidosis in severe infection
- Pulmonary complications of kidney disease
Studies test new antimicrobial agents and supportive therapies to enhance recovery and reduce exacerbations.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 2 of 12 therapeutic areas and 15 of 167 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 160 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 34 by active trials.
- 1GPOH gGmbH7active
lock +33 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1GPOH gGmbH7trials
lock +13 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Klinikum Dortmund gGmbH
lock Showing 1 of 66 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| 2022-501606-35-00 – Randomized, multicenter, open-label, Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with FRα-high recurrent platinum-sensitive epithelial ovarian, fallopian tube, or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA). | AbbVie Deutschland GmbH & Co. KG | Phase I | Not Yet Recruiting | Feb 2024 | — |
IMP list
lock Showing 1 of 167 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Carboplatin | 14 | Unknown | 2018-03-06 | 2025-12-18 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.